Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods. A pharmacoeconomic model based on clinical da...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
Formato: Artigo
Idioma:Russo
Publicado em: IRBIS LLC 2020-02-01
Colecção:Фармакоэкономика
Assuntos:
cost-effectiveness ratio
budget impact analysis
omalizumab
reslizumab
mepolizumab
Acesso em linha:https://www.pharmacoeconomics.ru/jour/article/view/315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados